🇺🇸 Abilify (aripiprazole) in United States

100 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 21 April 2025 – 21 April 2026
• Total reports: 100

Most-reported reactions

1. Fatigue — 14 reports (14%)
2. Diarrhoea — 12 reports (12%)
3. Insomnia — 12 reports (12%)
4. Depression — 10 reports (10%)
5. Nausea — 10 reports (10%)
6. Dizziness — 9 reports (9%)
7. Pain — 9 reports (9%)
8. Anxiety — 8 reports (8%)
9. Drug Ineffective — 8 reports (8%)
10. Headache — 8 reports (8%)

Source database →

Frequently asked questions

Is Abilify (aripiprazole) approved in United States?

Abilify (aripiprazole) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Abilify (aripiprazole) in United States?

Genovate Biotechnology Co., Ltd., is the originator. The local marketing authorisation holder may differ — check the official source linked above.